Clearside Biomedical (CLSD) said Wednesday its China-based partner, Arctic Vision, has received regulatory approvals in Australia and Singapore for Arcatus, an injection therapy for the treatment of uveitic macular edema.
Arcatus is the brand name used for Clearside's Xipere medication outside the US.
Arctic Vision, which has the exclusive license for the commercialization and development Xipere in the Asia-Pacific region, has received approvals for its new drug applications for Arcatus from the Therapeutic Goods Administration of Australia and the Health Sciences Authority in Singapore, Clearside said.
Shares of Clearside were up about 2% in recent trading.
Price: 0.94, Change: +0.02, Percent Change: +1.92
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。